Profiling Intestinal Microbiota to Predict Treatment Response in Severe Acute Alcoholic Hepatitis Patients

What this Trial Is About

Researchers are studying the intestinal microbiota in patients with severe acute alcoholic hepatitis sAH, a serious liver condition linked to alcohol-related changes in gut bacteria. The study aims to identify specific bacterial patterns associated with how patients respond to corticosteroid treatment combined with either fecal microbiota transplantation FMT or placebo. Understanding these bacterial fingerprints may help predict treatment outcomes and guide personalized therapy. Participants include three groups sAH patients, alcohol-dependent controls without liver complications, and healthy non-alcoholic individuals, matched by age and sex. The study involves collecting stool samples at the start and after seven days to analyze bacterial composition using advanced DNA sequencing techniques. Researchers will assess changes in microbiota and metabolic products like short-chain fatty acids, aiming to characterize dysbiosis linked to alcohol use and treatment response. During the study, stool samples will be collected at baseline and day 7. Researchers will analyze microbial DNA to compare bacterial composition changes between groups and evaluate metabolic activity. The main outcome is the variation in bacterial composition after one week of corticosteroid treatment. The study is double-blinded and non-randomized, with a participation age range of 18 to 75 years. The trial is sponsored by Centre Hospitalier Universitaire, Amiens, and includes healthy volunteers for comparison.

Intestinal Microbiota Profiling in Severe Acute Alcoholic Hepatitis Patients